Cytokine-induced killer cells as a feasible adoptive immunotherapy for the treatment of lung cancer

Abstract

Most of the patients with lung cancer are diagnosed at advanced stage, and they often lose the opportunity of surgical therapy, most of whom fail to reach good prognosis after chemotherapy. Recently, a few clinical studies have confirmed the role of adoptive T-cell transfer in the maintenance therapy of cancer patients. Here, we provided statistical insights into the role of CIKs in advanced lung cancer from three different levels, cell model (in vitro co-culture system), mice model (in situ lung cancer), and clinical research (in lung cancer patients of different progression stages). We optimized the components of supplements and cytokines on activating and expanding CIK cells. Based on this, we explored a new serum-free medium for in vitro activation and expansion of CIK cells. Moreover, we found that activated CIK cells could efficiently kill lung cancer cells in cell-to-cell model in vitro and significantly reduce the tumor growth in mice. For the clinical research, the OS rates of patients received combination of chemotherapy and CIK treatment were significantly improved compared to the OS rates of patients only received chemotherapy. Additionally, CIK therapy represented good toleration in our study. All the results suggested that combination of immunotherapy with traditional therapy will be a feasible and promising method for the treatment of lung cancer.

The role and therapeutic implications of T cells in cancer of the lung

“…In one recent study, Chen and colleagues found DC-activated CIK cells in combination with standard platinum-based doublet chemotherapy to be well tolerised and to significantly improve 3-year survival compared to chemotherapy alone in NSCLC patients (50.7% vs 33.8%, P = 0.036, n = 68/group). 42 Other forms of ACT have become an area of increased interest in lung oncology research. A randomised phase-III clinical trial (n = 101) assessed the efficacy of DC-activated CTL adoptive transfer combined with standard platinum-based chemotherapy for post-surgical NSCLC patients.…”

The value of Cone-Beam CT-guided radiofrequency ablation in the treatment of pulmonary malignancies (≤3 cm)

“…For the treatment of lung cancer, surgery, chemotherapy and radiotherapy are still the primary choice in the clinic. In recent years, immunotherapy and targeted therapy are gradually developed and bring great potential for these patients, such as cytokine-induced killer cells [3,4].…”

Emerging therapeutic potential of the iridoid molecule, asperuloside: A snapshot of its underlying molecular mechanisms

“…Generally, anti-angiogenic effects are modulated through multiple pathways. The key signalling pathway that modulates proliferation of endothelial cells is the vascular endothelium growth (50)(51)(52)(53)(54). In this study, CIK cells were generated by culturing peripheral blood monocytes isolated from healthy donors with interferon-gamma (IFN-) and interleukin-2.…”